Grupo 2
Oncología Médica Traslacional y Terapia Individualizada del Cáncer
Publicaciones (831)
-
Martinez-Trufero, J; De Sande-Gonzalez, LM; Luna, P; Martin-Broto, J; Alvarez, R; Marquina, G; Diaz-Beveridge, R; Poveda, A; Cano, JM; Cruz-Jurado, J; Pousa, AL; Salgado, MAV; Valverde-Morales, CM; Sevilla, I; Martinez-Garcia, J; Rubio-Casadevall, J; De Juan, A; Carrasco, JA; Moura, DS; Gurruchaga-Sotes, I; Gutierrez, A.
A Growth Modulation Index-Based GEISTRA Score as a New Prognostic Tool for Trabectedin Efficacy in Patients with Advanced Soft Tissue Sarcomas: A Spanish Group for Sarcoma Research (GEIS) Retrospective Study
Cancers. 2021; 13(4): Nº de citas: 8 [doi:10.3390/cancers13040792]
-
Mayer, EL; Dueck, AC; Martin, M; Rubovszky, G; Burstein, HJ; Bellet-Ezquerra, M; Miller, KD; Zdenkowski, N; Winer, EP; Pfeiler, G; Goetz, M; Ruiz-Borrego, M; Anderson, D; Nowecki, Z; Loibl, S; Moulder, S; Ring, A; Fitzal, F; Traina, T; Chan, A; Rugo, HS; Lemieux, J; Henao, F; Lyss, A; Novoa, SA; Wolff, AC; Vetter, M; Egle, D; Morris, PG; Mamounas, EP; Gil-Gil, MJ; Prat, A; Fohler, H; Metzger, O; Schwarz, M; DuFrane, C; Fumagalli, D; Theall, KP; Lu, DR; Bartlett, CH; Koehler, M; Fesl, C; DeMichele, A; Gnant, M.
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
LANCET ONCOLOGY. 2021; 22(2): 212-222 Nº de citas: 223 [doi:10.1016/S1470-2045(20)30642-2]
-
Chan, A; Moy, B; Mansi, J; Ejlertsen, B; Holmes, FA; Chia, S; Iwata, H; Gnant, M; Loibl, S; Barrios, CH; Somali, I; Smichkoska, S; Martinez, N; Alonso, MG; Link, JS; Mayer, IA; Cold, S; Murillo, SM; Senecal, F; Inoue, K; Ruiz-Borrego, M; Hui, RN; Denduluri, N; Patt, D; Rugo, HS; Johnston SRD; Bryce, R; Zhang, B; Xu, F; Wong, A; Martin, M; ExteNET Study Group.
Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial
CLINICAL BREAST CANCER. 2021; 21(1): 80 Nº de citas: 180 [doi:10.1016/j.clbc.2020.09.014]
-
Laria, JC; Aguilera-Morillo, MC; Alvarez, E; Lillo, RE; Lopez-Taruella, S; del Monte-Millan, M; Picornell, AC; Martin, M; Romo, J.
Iterative Variable Selection for High-Dimensional Data: Prediction of Pathological Response in Triple-Negative Breast Cancer
Mathematics. 2021; 9(3): Nº de citas: 3 [doi:10.3390/math9030222]
-
Ruiz-Pinto, S; Pita, G; Martin, M; Nunez-Torres, R; Cuadrado, A; Shahbazi, MN; Caronia, D; Kojic, A; Moreno, LT; de la Torre-Montero, JC; Lozano, M; Lopez-Fernandez, LA; Ribelles, N; Garcia-Saenz, JA; Alba, E; Milne, RL; Losada, A; Perez-Moreno, M; Benitez, J; Gonzalez-Neira, A.
Regulatory CDH4 Genetic Variants Associate With Risk to Develop Capecitabine-Induced Hand-Foot Syndrome
CLINICAL PHARMACOLOGY & THERAPEUTICS. 2021; 109(2): 462-470 Nº de citas: 5 [doi:10.1002/cpt.2013]
-
Custodio-Cabello, S; Cabezon-Gutierrez, L; Palka-Kotlowska, M; Acebes, EO; Khosravi-Shahi, P.
Ant-EGFR Antibody Plus Chemotherapy Treatment in a Patient with Synchronous Merkel Cell Carcinoma and Colorectal Cancer
CUREUS JOURNAL OF MEDICAL SCIENCE. 2021; 13(1): [doi:10.7759/cureus.12916]
-
Schettini, F; Chic, N; Braso-Maristany, F; Pare, L; Pascual, T; Conte, B; Martinez-Saez, O; Adamo, B; Vidal, M; Barnadas, E; Fernandez-Martinez, A; Gonzalez-Farre, B; Sanfeliu, E; Cejalvo, JM; Perrone, G; Sabarese, G; Zalfa, F; Peg, V; Fasani, R; Villagrasa, P; Gavila, J; Barrios, CH; Lluch, A; Martin, M; Locci, M; De Placido, S; Prat, A.
Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer
Npj Breast Cancer. 2021; 7(1): 1-1 Nº de citas: 460 [doi:10.1038/s41523-020-00208-2]
-
Gonzalez-Cao, M; Puertolas, T; Riveiro, M; Munoz-Couselo, E; Ortiz, C; Paredes, R; Podzamczer, D; Manzano, JL; Molto, J; Revollo, B; Carrera, C; Mateu, L; Fancelli, S; Espinosa, E; Clotet, B; Martinez-Picado, J; Cerezuela, P; Soria, A; Marquez, I; Mandala, M; Berrocal, A; Spanish Melanoma Grp GEM.
Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)
Journal for ImmunoTherapy of Cancer. 2021; 9(3): Nº de citas: 12 [doi:10.1136/jitc-2020-001664]
-
Navarro S; Cuatrecasas M; Hernández-Losa J; Landolfi S; Musulén E; Ramón Y Cajal S; García-Carbonero R; García-Foncillas J; Pérez-Segura P; Salazar R; Vera R; García-Alfonso P.
Actualización de la recomendación para la determinación de biomarcadores en el carcinoma colorrectal. Consenso Nacional de la Sociedad Española de Oncología Médica y de la Sociedad Española de Anatomía Patológica.
Revista Espanola de Patologia. 2021; 54(1): 41-54 [doi:10.1016/j.patol.2020.07.004]
-
Aparicio, J; del Muro, XG; Maroto, P; Terrasa, J; Castellano, D; Bastus, R; Guma, J; Sagastibeltza, N; Duran, I; Ochenduszko, S; Meana, JA; Garcia-Sanchez, J; Arranz, JA; Girones, R; Germa, JR.
Patterns of relapse and treatment outcome after active surveillance or adjuvant carboplatin for stage I seminoma: a retrospective study of the Spanish Germ Cell Cancer Group
CLINICAL & TRANSLATIONAL ONCOLOGY. 2021; 23(1): 58-64 Nº de citas: 9 [doi:10.1007/s12094-020-02393-9]
-
Garcia-Alfonso, P; Garcia-Gonzalez, G; Gallego, I; Peligros, MI; Ortega, L; Perez-Solero, GT; Sandoval, C; Martin, AM; Codesido, MB; Ferrandiz, AC; Martin, M.
Prognostic value of molecular biomarkers in patients with metastatic colorectal cancer: a real-world study
CLINICAL & TRANSLATIONAL ONCOLOGY. 2021; 23(1): 122-129 Nº de citas: 3 [doi:10.1007/s12094-020-02402-x]
-
Lopez, MDG; Rodas, IM; Pujol, CA; Perez, AG; Saachez, EV; Alvarez, RA.
Simultaneous diagnosis of liver PEComa in a family with known Li-Fraumeni syndrome: a case report
Clinical Sarcoma Research. 2020; 10(1): Nº de citas: 7 [doi:10.1186/s13569-020-00143-7]
-
Fasching, PA; Beck, JT; Chan, A; De Laurentiis, M; Esteva, FJ; Jerusalem, G; Neven, P; Pivot, X; Bianchi, GV; Martin, M; Chandiwana, D; Lanoue, B; Ridol, A; Wang, YB; Lorenc, KR; Nusch, A.
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study
BREAST. 2020; 54: 148-154 Nº de citas: 34 [doi:10.1016/j.breast.2020.09.008]
-
Molins, JB; Jimenez, JGD; Valderrama, BP; Echaburu, JAV; Hernando-Polo, S; Duran, MAC; Villa-Guzman, JC; Arija, JAA; Ostiategui, ML; Milagro, NL; Gonzalez-del-Alba, A; Gonzalez, BM; Diaz, EG; Gauna, DC; Santasusana, MD; Herranz, UA; Solans, XGD; Perez-Gracia, JL; Vazquez, JP; Morales-Barrera, R; Pous, AF.
Final Overall Survival Analysis of the SOGUG Phase 2 MAJA Study: Maintenance Vinflunine Versus Best Supportive Care After First-Line Chemotherapy in Advanced Urothelial Carcinoma
CLINICAL GENITOURINARY CANCER. 2020; 18(6): 452-460 Nº de citas: 11 [doi:10.1016/j.clgc.2020.05.004]
-
Munoz-Unceta, N; Zugazagoitia, J; Manzano, A; Jimenez-Aguilar, E; Olmedo, ME; Cacho, JD; Oliveira, J; Domine, M; Ortega-Moran, L; Aguado, C; Luna, AM; Fernandez, L; Perez, J; Font, C; Salvador, C; Corral, J; Benitez, G; Ros, S; Biosca, M; Calvo, V; Martinez, J; Sanchez-Canovas, M; Lopez, R; Sereno, M; Mielgo, X; Aparisi, F; Carmona, M; Carrion, R; Ponce-Aix, S; Soares, M; Martinez-Salas, I; Garcia-Morillo, M; Juan-Vidal, O; Blasco, A; Munoz, AJ; Paz-Ares, L; Grp Trombosis & Canc SEOM.
High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1
EUROPEAN JOURNAL OF CANCER. 2020; 141: 193-198 Nº de citas: 22 [doi:10.1016/j.ejca.2020.10.002]
-
Rubio, VEC; Perez-Segura, P; Munoz, A; Farre, AL; Ruiz, LC; Lorente, JA.
High plasma levels of soluble P-Selectin and Factor VIII predict venous thromboembolism in non-small cell lung cancer patients: The Thrombo-Nsclc risk score
THROMBOSIS RESEARCH. 2020; 196: 349-354 Nº de citas: 26 [doi:10.1016/j.thromres.2020.09.021]
-
Johnston, SRD; Harbeck, N; Hegg, R; Toi, M; Martin, M; Shao, ZM; Zhang, QY; Rodriguez, JLM; Campone, M; Hamilton, E; Sohn, J; Guarneri, V; Okada, M; Boyle, F; Neven, P; Cortes, J; Huober, J; Wardley, A; Tolaney, SM; Cicin, I; Smith, IC; Frenzel, M; Headley, D; Wei, R; San Antonio, B; Hulstijn, M; Cox, J; O'Shaughnessy, J; Rastogi, P; Behalf MonarchE Comm Members Inve.
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
JOURNAL OF CLINICAL ONCOLOGY. 2020; 38(34): Nº de citas: 698 [doi:10.1200/JCO.20.02514]
-
Gonzalez-del-Alba, A; Arranz, JA; Bellmunt, J; Maroto, JP; Fernandez-Calvo, O; Valderrama, BP; Gonzalez-Billalabeitia, E; Mendez-Vidal, MJ; Cassinello, J; Romero-Laorden, N; Climent, MA; Puentel, J; Pelaez, I; Lazaro-Quintela, M; Gallardo, E; Suarez, C.
Latest progress in molecular biology and treatment in genitourinary tumours
CLINICAL & TRANSLATIONAL ONCOLOGY. 2020; 22(12): 2175-2195 [doi:10.1007/s12094-020-02373-z]